PREDI-LYNCH sets out to make a difference for people with Lynch syndrome (LS) by developing and implementing novel, non-invasive early detection methods for colorectal, endometrial and urothelial cancers in patients with LS. The research team addresses an unmet medical need in providing an innovative approach to biomarker discovery for early-stage cancers in LS patients.
PREDI-LYNCH will focus on improving cancer surveillance in LS to detect cancers at an early stage, utilising effective and minimally invasive strategies, so as to improve patient outcomes and compliance.
- Develops non-invasive liquid biopsy tests for early cancer detection in individuals with Lynch syndrome.
- Combines artificial intelligence, biomarker technology, and clinical expertise to improve the quality of life and healthcare for at-risk groups.
- Is a collaborative consortium involving 28 organisations from 16 European countries.
- Received €13.6 million in Horizon Europe funding. Horizon Europe is the EU’s key research and innovation funding programme aimed at promoting scientific breakthroughs and collaborations to solve global challenges.
- The project will begin in June 2025 and end in summer 2031.
Lynch Syndrome Ireland 